# Coherus Oncology, Inc. (CHRS) — delisting/forced [announced]
Source: sec.gov · situation sit_1bf2cc8ffbb579ae0c9d · public 8976180018346870565 · retrieved 2026-08-20T13:15:00.241Z

## Overview
Coherus Oncology, Inc. is a biopharmaceutical company developing oncology product candidates.

Coherus Oncology, Inc. and certain wholly owned subsidiaries entered into a Loan and Security Agreement dated August 12, 2026 with Innovatus Life Sciences Lending Fund I, LP as collateral agent and other lenders. The lenders agreed to provide a senior secured term loan facility of $55,000,000 (Tranche A Term Loan) with a maturity date in August 2031. On August 14, 2026, the Company drew the full $55,000,000 and used a portion to repay all obligations under its existing senior secured term loan facility, which had been scheduled to mature in May 2029 and carried an interest rate of 8.0% plus three-month SOFR. The new facility accrues interest at a floating rate of 4.15% plus the greater of the Prime Rate or 6.75%, with interest-only payments for an initial 36-month period (extendable to 48 months upon achievement of specified revenue and market capitalization milestones), followed by consecutive equal monthly principal and interest payments over the remaining term.

## Terms
- Counterparty: Innovatus Life Sciences Lending Fund I, LP · Deal value: $55.0M · Consideration: cash

## Key dates
- Announced 2026-08-17

## Timeline
- 2026-08-17 · 8-K (0001104659-26-097949): 8-K - Coherus Oncology, Inc. — *Coherus Oncology, Inc. is a biopharmaceutical company developing oncology product candidates.* Coherus Oncology, Inc. and certain wholly owned subsidiaries entered into a Loan and Security Agreement dated August 12, 2026 with Innovatus Life Sciences Lending Fund I, LP as collateral agent and other lenders. The lenders agreed to provide a senior secured term loan facility of $55,000,000 (Tranche A Term Loan) with a maturity date in August 2031. On August 14, 2026, the Company drew the full $55,000,000 and used a portion to repay all obligations under its existing senior secured term loan facility, which had been scheduled to mature in May 2029 and carried an interest rate of 8.0% plus three-month SOFR. The new facility accrues interest at a floating rate of 4.15% plus the greater of the Prime Rate or 6.75%, with interest-only payments for an initial 36-month period (extendable to 48 months upon achievement of specified revenue and market capitalization milestones), followed by consecutive equal monthly principal and interest payments over the remaining term.
  https://www.sec.gov/Archives/edgar/data/1512762/0001104659-26-097949.txt

## Citations
- 0001104659-26-097949 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926097949